Diplomat Pharmacy (DPLO) Misses Q2 EPS by 6c; Lowers EPS Outlook

Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.17, $0.06 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.42 billion.

GUIDANCE:

Diplomat Pharmacy maintains FY2018 revenue of $5.5-5.9 billion, versus the consensus of $5.67 billion. Diluted EPS between $(0.15) and $0.01, versus the previous range of $0.06 and $0.17

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance